All News

The combination of Opdivo and Yervoy is showing promise as a treatment for PD-L1-Positive Non-Small Cell Lung Cancer, according to the results of a recent study.

Opdivo showed a higher-than-average OS rate and presented no grade 3/4 adverse events in patients with recurrent glioblastoma multiforme, according to a recent study.

When life feels really big, it's natural to see only the worst case scenario. It's natural to see catastrophe looming. Whether or not a catastrophe is on the horizon, it is out of our control. So perhaps it is more fruitful to keep ourselves in the here and now, in order to live our best life possible.

This cancer survivor still struggles with scanxiety and the cancer waiting and watching game.

Patients treated with Xtandi had higher rates of fatigue and pain than those who were treated with Zytiga and prednisone, resulting in a higher likelihood that they will reduce their treatment dose.

Tumor Treating Fields were determined safe to use as a fronline therapy for unresectable pancreatic cancer.

The experimental immunotherapy avelumab demonstrated durable responses and promising early survival data for patients with pretreated metastatic Merkel cell carcinoma.

Multiplex gene testing may not bring about unnecessary surgery or adverse psychological effects, according to findings from a recent study.

A population-based study revealed that less black women are tested or treated for BRCA mutations when compared with white and Hispanic women.

The battle does not always end with the word.

Ed's weakened immune system plagues him for the last time.

According to results from a phase 3 study, Opdivo improved overall survival and objective response rates for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Phase 2 data presented at ASCO showed that Tafinlar plus Mekinist was a highly effective treatment regimen for patients with BRAF V600E-mutant NSCLC.

Binimetinib, an experimental targeted drug, reduced the risk of disease progression or death in patients with NRAS-mutant metastatic melanoma in a recent phase 3 study.

In a recent study, patients with lung cancer who used an online app to track their symptoms saw a higher overall survival rate than those who didn't.

If you really break it down, there are only two emotions that consume the world and all its living beings: love and fear.

Ed's weakened immune system continues to haunt him.

At the 2016 ASCO Annual Meeting, the vice president called for a commitment to team science, improved patient access to clinical trials, and announced a new cancer genomic and clinical data-sharing resource.

Aggressive end-of-life care is often harmful to patients and their families, yet is still so widely used.

In the longest follow-up of an anti-PD-1 immunotherapy in RCC, about one-third of the patients treated with single-agent Opdivo are still alive four and five years later.

Women are reducing their risk of recurrence by extending their adjuvant therapy with an aromatase inhibitor (AI) to 10 years after treatment for their early-stage HR-positive breast cancer.

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

Breast cancer can bring the surprise of lymphedema to the unsuspecting, uniformed patient.

People across the nation are participating in the Metastatic Breast Cancer (MBC) Project to help researchers steer the approach in fighting the disease.

A recent study showed that adding chemotherapy to radiotherapy after surgery for glioblastoma resulted in improved survival for elderly patients.

Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase 2a basket study.

Though more research still needs to be done, potential for liquid biopsies was shown in a study involving 15,000 patients who represented a multitude of cancer types.

This study was presented in conjunction with the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.